Abstract
We correlated age and body surface area corrected glomerular filtration rate (GFR) at the time of high-dose melphalan (HDM) administration with treatment-related toxicity (TT), time to disease progression and survival. Between 8/85 and 6/98, 144 newly diagnosed myeloma patients with a median age of 53 years (range, 31–72) received infusional chemotherapy with vincristine, doxorubicin and methylprednisolone, with/without cyclophosphamide or verapamil, followed by HDM 200 mg/m2and stem cell rescue. An additional patient received HDM at diagnosis. GFR was below normal in 38 patients (26%). At presentation, patients with low GFR at the time of HDM had higher serum creatinine, β2M, stage III disease, calcium and Bence–Jones proteinuria. Toxic deaths post-HDM were similar in both groups (2/38 (5%) vs. 4/107 (4%)), though patients with low GFR had more oral mucositis (P< 0.0001), diarrhoea (P = 0.005) and infections (P = 0.04). The response and relapse rates of the 2 groups were not substantially different, but the median overall survival (OS) was significantly shorter in patients with low GFR (5.1 vs 7.5 years, P = 0.015). Multivariate analysis showed that a normal GFR and being in CR at the time of HDM were predictive of longer OS. We conclude that in context of high-dose chemotherapy for myeloma, dose of melphalan should not be modified in patients with low GFR and that early intensive treatment at relapse may improve results in patients with abnormal renal function. © 2001 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Cassassus P, Maisonneuve H, Facon T, Ifrah N, Payen C and Bataille R (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 335: 91–97
Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegal D, Tricot G, Munshi N, Fassas A, Singhal S, Mehta J, Anaissie E, Dhodapkar D, Naucke S, Cromer J, Sawyer J, Epstein J, Spoon D, Ayers D, Cheson B and Crowley J (1999) Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 93: 55–65
Bjorkstrand B, Goldstone AH, Ljungman P, Brandt L, Brunet S, Carlson K, Prentice HG, Cavo M, Samson D, Laurenzi AD, Verdonck LF, Proctor S, Ferrant A, Sierra J, Auzanneau G, Troussard X, Gravett P, Remes K and Gahrton G (1994) Prognostic factors in autologous stem cells transplantation for multiple myeloma: an EBMT Registry study. Leuk Lymphoma 15: 265–272
BMDP statistical software release (1992). BMDP Statistical Software Manual, University of California Press: Berkeley 2: 825–866
Britton KE, Nimmon CC, Whitfield HN, Hendry WF and Wickham JEA (1979) Obstructive nephropathy: successful evaluation with radionuclides. Lancet i: 905
Brochner-Mortensen J (1978) Routine methods and their reliability for assessment of glomerular filtration rate in adults. Danish Medical Bulletin 25: 80–98
Cox DR (1972) Regression models and life tables. Journal of Royal Statistical Society of Britain 24: 187–220
Cunningham D, Paz-Ares L, Milan S, Powles R, Nicolson M, Hickish T, Selby P, Treleaven J, Viner C, Malpas J, Slevin M, Findlay M, Raymond J and Gore ME (1994) High dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J Clin Oncol 12: 759–736
Cunningham D, Powles RL, Malpas J, Raje N, Milan S, Viner C, Montes A, Hickish T, Nicolson M, Johnson P, Treleaven J, Raymond J and Gore M (1998) A randomised trial of maintenance interferon following high dose chemotherapy in multiple myeloma; long term follow up results. Br J Haematol 102: 495–502
Durie BGM and Salmon SE (1975) A clinical staging system for multiple myeloma. Cancer 36: 842–854
Forgeson GV, Selby P, Lakhani S, Sulian G, Viner C, Maitland J and McElwain TJ (1988) Infused vincristine and adriamycin with high dose methylprednisolone (VAMP) in advanced previously treated multiple myeloma patients. Br J Cancer 58: 469–473
Gore ME, Selby PJ, Millar B, Maitland J and McElwain TJ (1988) The use of verapamil to overcome drug resistance in myeloma. Proc Am Soc Clin Oncol 7: 228
Gore ME, Selby PJ, Viner C, Clark PI, Meldrum H, Millar B, Bell J, Maitland JA, Milan S, Judson IR, Suiable A, Tillyer C, Slevin M, Malpas JS and McElwain TJ (1989) Intensive treatment of Multiple Myeloma and criteria for complete remission. Lancet 2: 879–881
Kaplan EL and Meier P (1958) Non parametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481
Kasiske BL and Keane WF (1996). Laboratory assessment of renal disease: Clearance, urinanalysis and renal biopsy, Brenner BM, Rector FC Jr (eds)The Kidney, Philadelphia,PA, Saunders pp. 1137–1173
Kergueris MF, Milpied N, Moreau N, Harousseau JL and Larousse C (1994) Pharmacokinetics of high-dose melphalan in adults: influence of renal function. Anticancer Res 14: 2379–2382
Kruskal WH and Wallis WA (1952) Use of ranks in one-criterion variance analysis. J Am Stat Assoc 47: 583–621
Labeeuw M, Diaz C, Cailette A, Aissa AH and Pozet N (1994) Estimation of GFR from serum creatinine in elderly patients: comparison of several methods. J Am Soc Nephrol 5: 336a
Leblanc M and Crowley J (1993) Survival trees by goodness of split. J Am Stat Assoc 88: 457–467
Mansi J, Da Costa F, Viner C, Judson I, Gore M and Cunningham D (1991) High dose busulfan in patients with myeloma. J Clin Oncol 10: 1569–1573
Medical Research Council Working Party on Leukemia in adults (1980) Prognostic features in the third MRC myelomatosis trial. British Journal of Cancer 42: 831–840
Merlini G, Waldenstrom JG and Jayakar S (1980) A new improved clinical staging system for multiple myeloma based on analysis of 123 treated patients. Blood 55: 1011–1019
Miller AB, Hoogstraten B, Staquet M and Winkler A (1981) Reporting results of Cancer treatment. Cancer 47: 207–214
Moreau P, Milpied N, Mahe B, Juge-Morineau N, Rapp M-J, Bataille R and Harousseau J-L (1999) Melphalan 220 mg/m2followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma. Bone Marrow Transplant 23: 1003–1006
Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J and Smith PG (1977) Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II, Analysis and examples. Br J Cancer 35: 1–39
Powles R, Raje N, Milan S, Millar B, Shepherd V, Mehta J, Singhal S, Kulkarni S, Viner C, Gore M, Cunningham D and Treleaven J (1997) Outcome assessment of a population based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment. Bone Marrow Transplant 20: 435–443
Raje N, Powles R, Kulkarni S, Milan S, Middleton G, Singhal S, Mehta J, Millar B, Viner C, Raymond J and Treleaven J (1997a) A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (C-VAMP) as induction treatment followed by autografting in previously untreated myeloma. Br J Haematol 97: 153–160
Raje N, Powles R, Horton C, Millar B, Shepherd V, Middleton G, Kulkarni S, Eisen T, Mehta J, Singhal S and Treleaven J (1997b) Comparison of marrow vs blood derived stem cells for autografting in previously untreated multiple myeloma. Br J Cancer 75: 1684–1689
Selby P, Zulian G, Forgeson G, Nandi A, Milan S, Meldrum M, Viner C, Osborne R, Malpas JS and McElwain TJ (1988) The development of high-dose melphalan and of autologous bone marrow transplantation in the treatment of multiple myeloma: Royal Marsden and St Bartholomew's Hospital studies. Haematol Oncol 6: 173–179
Siegel DS, Desikan KR, Mehta J, Singhal S, Fassas A, Munshi N, Annaissie E, Naucke S, Ayers D, Spoon D, Vesole D, Tricot G and Barlogie B (1999) Age is not a prognostic variable with autotransplants for multiple myeloma. Blood 93: 51–54
Sirohi B, Powles R, Treleaven J, Singhal S, Kulkarni S, Parikh P, Bhagwati N, Horton C and Mehta J (1999a) The implication of compromised renal function at the time of presentation in myeloma: a single centre study of 251 patients. Blood 94: Suppl 1, 575a
Sirohi B, Powles R, Mehta J, Raje N, Kulkarni S, Ramiah V, Saso R, Horton C, Bhagwati N, Singhal S and Treleaven J (1999b) Complete remission rate and outcome after intensive treatment of 177 patients under 75 years of age with IgG myeloma defining a circumscribed disease entity with a new staging system. Br J Haematol 107: 656–666
Sirohi B, Powles R, Treleaven J, Mainwaring P, Kulkarni S, Pandha H, Bhagwati N, Horton C, Singhal S and Mehta J (2000) The role of autologous transplantation in patients with multiple myeloma aged 65 years and over. Bone Marrow Transplant 25: 533–539
Toto RD, Kirk KA, Coresh J, Jones C, Appel L, Wright J, Campese V, Oltunde B and Agodoa L AASK Pilot Study Investigators (1997) Evaluation of serum creatinine for estimating glomerular filtration rate in blacks with hypertensive nephrosclerosis: Results from the African-American Study of Kidney disease and hypertension (AASK) Pilot study. J Am Soc Nephrol 8: 279–287
Tricot G, Alberts DS, Johnson C, Roe DJ, Dorr RT, Bracy D, Vesole DH, Jagannath S, Meyers R and Barlogie B (1996) Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study. Clin Cancer Res 2: 947–952
Vesole DH, Tricot G, Jagannath S, Desikan KR, Siegel D, Bracy D, Langdon M, Cheson B, Crowley J and Barlogie B (1996) Autotransplants in multiple myeloma: what have we learned?. Blood 88: 838–847
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Sirohi, B., Powles, R., Kulkarni, S. et al. Glomerular filtration rate prior to high-dose melphalan 200 mg/m2as a surrogate marker of outcome in patients with myeloma. Br J Cancer 85, 325–332 (2001). https://doi.org/10.1054/bjoc.2001.1928
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.1928
Keywords
This article is cited by
-
Gastrointestinal toxicity of high-dose melphalan in autologous hematopoietic stem cell transplantation: identification of risk factors and a benchmark for experimental therapies
Annals of Hematology (2021)
-
Lower glomerular filtration rate predicts increased hepatic and mucosal toxicity in myeloma patients treated with high-dose melphalan
International Journal of Hematology (2018)
-
Variability of high-dose melphalan exposure on oral mucositis in patients undergoing prophylactic low-level laser therapy
Lasers in Medical Science (2017)
-
Melphalan 200 mg/m2 in patients with renal impairment is associated with increased short-term toxicity but improved response and longer treatment-free survival
Bone Marrow Transplantation (2016)
-
Renal failure in multiple myeloma: a medical emergency
Bone Marrow Transplantation (2011)